Simplex Trading
CTMX icon

Simplex Trading’s CytomX Therapeutics CTMX Stock Holding History

Simplex Trading’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Sell
31,100
-280,800
-90% -$1.07M ﹤0.01% 5353
2026
Q1 		$1.47M Buy
311,900
+310,700
+25,892% +$1.58M ﹤0.01% 2106
2025
Q4 		$5.11K Sell
1,200
-11,000
-90% -$41.8K ﹤0.01% 7419
2025
Q3 		$38K Sell
12,200
-16,600
-58% -$37.4K ﹤0.01% 6717
2025
Q2 		$65K Buy
+28,800
New +$46.4K ﹤0.01% 5656
2023
Q2 		– Sell
-1,800
Closed -$2K – 9115
2023
Q1 		$2K Buy
+1,800
New +$4.07K ﹤0.01% 8431
2022
Q2 		– Sell
-1,200
Closed -$3K – 10112
2022
Q1 		$3K Sell
1,200
-500
-29% -$1.92K ﹤0.01% 9675
2021
Q4 		$7K Buy
1,700
+300
+21% +$1.76K ﹤0.01% 9283
2021
Q3 		$9K Hold
1,400
– – ﹤0.01% 8984
2021
Q2 		$8K Buy
1,400
+1,390
+13,900% +$10.8K ﹤0.01% 9203
2021
Q1 		$7K Buy
+10
New +$79 ﹤0.01% 8062
2017
Q4 		– Sell
-3
Closed -$1K – 6080
2017
Q3 		$1K Buy
+3
New +$47 ﹤0.01% 5383

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Simplex Trading's CTMX Position: Q2 2026 in Review

Simplex Trading reduced its CytomX Therapeutics (CTMX) stake by 96% in Q2 2026, selling an estimated $909K and leaving 10,286 shares worth $38.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6542.

Simplex Trading first reported a position in CTMX in Q3 2017 and has held it in 18 quarters since. The position peaked at $1.17M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Simplex Trading held 10,286 shares of CytomX Therapeutics worth $38.6K as of Q2 2026.
  • Simplex Trading sold 238,152 CytomX Therapeutics shares in Q2 2026, an estimated $909K.
  • CytomX Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6542 holding.
  • Simplex Trading first reported a position in CytomX Therapeutics in Q3 2017 and has held it in 18 quarters since.
  • Simplex Trading's CytomX Therapeutics position peaked at $1.17M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.